11月6日 - ** 生物技术公司Alvotech ALVO.O的股票在早盘交易中上涨2.4%，达到5美元
** ALVO与私营公司Advanz Pharma共同表示，英国药品监管机构已经批准了Gobivaz，这是强生JNJ.NSimponi的生物仿制药，可用于类风湿性关节炎和溃疡性结肠炎等免疫相关疾病。
** 公司表示，Gobivaz将有两种强度，预灌封注射器和自动注射器两种规格
** ALVO 表示，Alvotech 负责开发和供应该药物，而 Advanz Pharma 则拥有该药物在欧洲和英国的独家销售权。
** 包括盘中走势在内，股价下跌约 63
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.